PharmaCyte Biotech, Inc. is a biotechnology company, which is focused on developing cellular therapies for cancer based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including locally advanced, inoperable pancreatic cancer (LAPC) will be developed. The Cell-in-a-Box encapsulation technology potentially enables genetically engineered live human cells to be used as a means to produce various biologically active molecules. The technology is intended to result in the formation of pinhead-sized cellulose-based porous capsules in which genetically modified live human cells can be encapsulated and maintained. In a laboratory setting, this proprietary live cell encapsulation technology has been shown to create a micro-environment in which encapsulated cells survive and flourish.
BörsenkürzelPMCB
Name des UnternehmensPharmaCyte Biotech Inc
IPO-datumSep 11, 2003
CEOSilverman (Joshua N)
Anzahl der mitarbeiter2
WertpapierartOrdinary Share
GeschäftsjahresendeSep 11
Addresse3960 Howard Hughes Parkway, Suite 500
StadtLAS VEGAS
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl89169
Telefon19175952850
Websitehttps://pharmacyte.com/
BörsenkürzelPMCB
IPO-datumSep 11, 2003
CEOSilverman (Joshua N)
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten